lower pt higher opex maintain outperform
updat model follow result
consensu estim revenu adjust earn manag top-
line guidanc higher estim howev earn guidanc rel
light given increas opex support new launch pipelin invest
maintain outperform rate lower pt vs primarili due higher
opex follow year solid pipelin execut expect momentum
commerci execut clinical/regulatori catalyst current trade
level continu view attract invest opportun expect
lubrinectedin updat key near-term catalyst
model revenu pt includ lurbinectedin
quarter report xyrem revenu full compani revenu
estim consensu xyrembottl volum
activ patient therapi grew adjust ep higher vs
estim driven higher revenu lower non-gaap tax rate vs
estim
messag view key messag oper
expens continu grow meaning manag believ
invest leverag time pipelin new launch
matur invest us sleep oncolog franchis contribut opex
item note earli sunosi trend show strong uptak among osa
patient addit narcolepsi patient manag believ xyrem patient
could immedi transit equival dose major payor
contract provid broad access across sleep franchis manag
anticip may experi market access issu launch
model updat leav revenu unchang lower adjust
earn higher oper expens key
contributor lower earn note impact account chang
requir compani longer exclud up-front mileston payment
non-gaap adjust net incom therefor expens up-front
payment pharmamar
catalyst regulatori action launch
lurbinectedin regulatori action around phase atlanti data mid-
year defitelio phase interim analysi vod prevent
interim analysi bla submiss like
year price histori
biopharmaceut compani focus
identif develop
commerci pharmaceut
product area cns-relat
sleep disrupt hematolog
analyst certif import disclosur see disclosur
given divers portfolio product stabl cash flow
strong balanc sheet believ well posit drive
continu growth intern invest strateg
collabor leadership team laid groundwork
sustain sleep franchis post xyrem gener jazz cns-
relat sleep disord franchis solid base busi
establish cash flow-gener lead product xyrem
late-stag pipelin anticip could partial off-set xyrem
gener impact outsid sleep franchis note
xyrem growth declin post
launch eros post author gener entri
launch probabl adjust
single-digit defitelio growth near term vod treatment
popul probabl approv prevent vod
late
vyxeo grow modestli us share reach low single-
sunosi script share ed market reach outer
digit growth sg respect
higher market share sunosi
acceler vyxeo uptak eu us
defitelio approv vod prevent
lurbinectedin phase atlanti data mid-year pdufa
defitelio phase interim analysi vod prevent
regulatori action launch
interim analysi bla submiss like
delay regulatori pathway
weak uptak sunosi time
xyrem gener enter prior
target price base blend discount cash flow sum-of-the-part analys model sale lead product ten-
year period assum termin valu base tail market product project period discount cash flow
use discount rate believ approxim compani weight averag cost capit base risk-
free rate expect market return beta per bloomberg assum termin growth rate
valuat attribut termin period
downsid risk includ xyrem gener enter prior slower anticip uptak sunosi delay regulatori
pathway higher oper expens
loss extinguish modif debt
interest expens incom
equiti loss investe
revenu
